The present study is the first demonstrating that KO supplementation downregulates the expression of PD-L1 and PD-L2 in the tumour tissues from mice with orthotopic CRC in the same manner as a full dose of oxaliplatin. The gene discussed is CD274; the disease is colorectal carcinoma.